Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors Proceeds will support the Phase 1/2 clinical development of lead program SB-007 in Stargardt disease, a genetic eye disorder that causes progressive...
Read More Details
Finally We wish PressBee provided you with enough information of ( EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio )
Also on site :